Tolvaptan
References
- Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Komatsu, Hajime; Tanaka, Michinori; Takara, Shinya; Tominaga, Michiaki; Yabuchi, Yoichi, Benzoheterocyclic compounds, Otsuka Pharmaceutical Co., Ltd., Japan, US5258510A, November 2, 1993
- Pei, Qi; Zhang, Bikui; Tan, Hongyi; Liu, Lihua; Peng, Xiangdong; Li, Zuojun; Huang, Panhao; Luo, Mi; Zuo, Xiaocong; Guo, Chengxian; et al, Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 913-914, Pages: 84-89, 2013
Frequently Asked Questions
Are there particular analytical techniques employed to ensure impurity control in Tolvaptan?
Many validated analytical methods, such as Reversed Phase high-performance liquid chromatography (RP-HPLC) coupled with a UV method, help detect and quantify impurities in Tolvaptan.
What measures help to minimize Tolvaptan impurities during the storage of the drug?
The proper storage conditions, such as temperature control and protection from light and moisture, help to minimize impurity formation.
Which solvent helps in the analysis of Tolvaptan impurities?
Methanol helps in analyzing many impurities in Tolvaptan.
What are the temperature conditions required to store Tolvaptan impurities?
Tolvaptan impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.